870640-61-2

Basic information

• Product Name: (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine
• Synonyms: (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine
• CAS NO: 870640-61-2
• Molecular Formula: C₁₆H₂₇NO₂
• Molecular Weight: 265.39108
• Mol File: 870640-61-2.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine(870640-61-2)
• EPA Substance Registry System: (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine(870640-61-2)

Safety Data

• Hazardous Substances Data: 870640-61-2(Hazardous Substances Data)

Usage

General Description

(2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine is a chiral amine compound with the chemical formula C17H29NO2. It is a synthetic derivative of amphetamine and is also known as supropyrrolidin. (2S,3S)-N-benzyl-1,1-dimethoxy-N,3-dimethylpentan-2-amine has a benzyl group attached to the amine nitrogen and two methoxy groups and three methyl groups attached to the pentan-2-amine backbone. It has potential applications in medicinal chemistry, particularly in the development of new psychoactive substances and pharmaceutical drugs. Additionally, it may also have applications in organic synthesis and as a reagent in chemical reactions. However, it is important to note that this compound may have significant regulatory restrictions and potential health hazards, and should only be handled and used by qualified professionals in appropriate laboratory settings.

Upstream product

• 67-56-1 methanol 
• 870640-63-4 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanal 
• 149-73-5 trimethyl orthoformate 
• 870640-62-3 (2S,3 S)-2-[benzyl(methyl)amino]-3-methylpentan-1-ol 
• 4125-97-7 (2S,3S)-2-(benzyl(methyl)amino)-3-methylpentanoic acid 
• 1859-49-0 (2S,3S)-2-(benzylamino)-3-methylpentanoic acid 
• 100-52-7 benzaldehyde 
• 73-32-5 L-isoleucine 
• 658691-27-1 C₁₃H₁₇NO₂ 

Downstream Products

• 120205-52-9 tert-butyl (3R,4S,5S)-4-[(2S)-2-[[(benzyloxy)carbonyl]amino]-N,3-dimethylbutanamido]-3-methoxy-5-methylheptanoate 
• 120205-48-3 tert-Butyl (3R,4S,5S)-3-methoxy-4-(N-methylamino)-5-methylheptanoate hydrochloride 
• 669074-47-9 methyl (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-amino-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate 
• 1438852-21-1 methyl (S)-2-((2R,3R)-3-((S)-1-((3R,4S,5S)-4-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropanamido)-3-phenylpropanoate 
• 870640-64-5 tert-butyl (3R,4S,5S)-4-[benzyl(methyl)amino]-3-methoxy-5-methyl heptanoate 

Relevant articles and documents

CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate or pharmaceutical composition comprising the same. From one aspect, the invention relates to an antibody-drug-conjugate (ADC) comprising an antibody consisting of the Trastuzumab or a biosimilar thereof, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment of cancer comprising administering to the subject an effective amount of said antibody-drug-conjugate or composition comprising the same.

IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER

The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS

The present invention concerns a compound of following formula (I) where: - R1 is H or OH, - R2 is a (C1-C6)alkyl, COOH, COO-((C1-C6)alkyl) or thiazolyl group, - R3 is H or a (C1-C6)alkyl group, and - R4 is: - an aryl-(C1-C8)alkyl group substituted by one or more groups chosen from among OH and NR9R10 groups, or - a heterocycle-(C1-C8)alkyl group optionally substituted by one or more groups chosen from among (C1-C6)alkyl, OH and NR12R13 groups, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and its uses in particular for the treatment of cancer, pharmaceutical compositions containing the same and the preparation methods thereof.